ClinicalTrials.gg
CompletedNCT00744263CAPITAUpdated Oct 6, 2014Results posted

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

A Phase 4 interventional study of VACCINE: placebo and VACCINE: 13-valent pneumococcal conjugate vaccine in Pneumonia, Pneumococcal, Pneumococcal Infections and 13-valent Pneumococcal Vaccine, sponsored by Pfizer. Completed at 159 sites in Netherlands. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-06.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84,496
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

02

Conditions studied

  • Pneumonia, Pneumococcal
  • Pneumococcal Infections
  • 13-valent Pneumococcal Vaccine
03

In context

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's enrollment of 84,496 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged 65 years or older on the day of vaccination and able to fulfill study requirements.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any licensed or experimental pneumococcal vaccine
  • Residence in a nursing home, long-term care facility, or similar facility
  • Known to vaccination
  • Immune deficiency or suppression
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84,496 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Biological: VACCINE: placebo

  • Experimental
    13-valent pneumococcal conjugate vaccine

    Biological: VACCINE: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)

    CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (\>) 38.0 degrees Celsius (C) or less than (\<) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15 percent (%) bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).

    Time frame: Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

Secondary outcomes

  1. Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)

    CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature \>38.0 degrees C or \<36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15% bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.

    Time frame: Baseline up to occurrence of first episode of NB/NI VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

  2. Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases

    VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).

    Time frame: Baseline up to occurrence of first episode of VT-IPD, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

Other outcomes

  1. Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination

    Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after vaccination

  2. Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination

    Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain \[new muscle/joint pain\], aggravated generalized muscle/joint pain \[aggravated muscle/joint pain\], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(\<38 degrees C); Mild(greater than or equal to \[\>=\]38 to \<38.5 degrees C); Moderate(\>=38.5 to \<39 degrees C); Severe(\>=39 to less than or equal to \[\<=\]40 degrees C); Potentially life threatening (\>40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours \[hrs\]); Moderate(\>2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(\>=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.

    Time frame: Within 7 days after vaccination

  3. Percentage of Participants Who Died

    Deaths collected throughout the case acquisition period were presented.

    Time frame: From signing of informed consent form up to case acquisition period defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

  4. Percentage of Participants With Newly Diagnosed Chronic Medical Condition

    Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.

    Time frame: From 1 month after vaccination up to 6 months after vaccination

07

Results

Posted Oct 6, 2014

Participant flow

Of 84496 participants who were randomized in this study, 2011 participants were included in the immunogenicity subset. Participants in the immunogenicity subset were analyzed for local reactions and systemic events as per planned analysis.

Participant flow — Overall Study
Milestone13vPnCPlacebo
Started4224042256
Completed3700436936
Not completed52365320
Withdrew: Death30063005
Withdrew: Lost to follow-up20382135
Withdrew: Withdrawal by subject166150
Withdrew: Physician decision2023
Withdrew: Protocol violation35
Withdrew: Adverse event10
Withdrew: Other22

Outcome measures

PrimaryNumber of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)

CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (\>) 38.0 degrees Celsius (C) or less than (\<) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15 percent (%) bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).

Time frame:
Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Reported as:
Number · participants
Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)
participants13vPnCPlacebo
Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)4990
Statistical analysis
  • 13vPnC vs Placebo · Clopper-Pearson method · p = 0.0006 · Vaccine efficacy: 45.56 · 95.2% CI 21.82 to 62.49
SecondaryNumber of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)

CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature \>38.0 degrees C or \<36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15% bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.

Time frame:
Baseline up to occurrence of first episode of NB/NI VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Reported as:
Number · participants
Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)
participants13vPnCPlacebo
Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)3360
Statistical analysis
  • 13vPnC vs Placebo · Clopper-Pearson method · p = 0.0067 · Vaccine efficacy: 45.00 · 95.2% CI 14.21 to 65.31
SecondaryNumber of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases

VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).

Time frame:
Baseline up to occurrence of first episode of VT-IPD, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Reported as:
Number · participants
Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases
participants13vPnCPlacebo
Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases728
Statistical analysis
  • 13vPnC vs Placebo · Clopper-Pearson method · p = 0.0005 · Vaccine efficacy: 75.00 · 95% CI 41.43 to 90.78
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination

Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination
percentage of participants13vPnCPlacebo
Redness: Any (n = 886, 859)4.9 (3.5 to 6.5)1.2 (0.6 to 2.1)
Redness: Mild (n = 886, 859)3.7 (2.6 to 5.2)0.8 (0.3 to 1.7)
Redness: Moderate (n = 881, 859)1.7 (1.0 to 2.8)0.3 (0.1 to 1.0)
Redness: Severe (n = 881, 859)0.5 (0.1 to 1.2)0.1 (0.0 to 0.6)
Swelling: Any (n = 888, 859)6.8 (5.2 to 8.6)1.2 (0.6 to 2.1)
Swelling: Mild (n = 888, 859)5.5 (4.1 to 7.2)0.7 (0.3 to 1.5)
Swelling: Moderate (n = 884, 859)2.6 (1.7 to 3.9)0.6 (0.2 to 1.4)
Swelling: Severe (n = 881, 859)0.1 (0.0 to 0.6)0.1 (0.0 to 0.6)
Pain: Any (n = 914, 863)36.1 (33.0 to 39.3)6.1 (4.6 to 8.0)
Pain: Mild (n = 913, 861)32.9 (29.8 to 36.0)5.6 (4.1 to 7.3)
Pain: Moderate (n = 886, 860)7.7 (6.0 to 9.6)0.6 (0.2 to 1.4)
Pain: Severe (n = 881, 860)0.3 (0.1 to 1.0)0.1 (0.0 to 0.6)
Limitation of arm movement: Any (n = 891, 865)14.1 (11.9 to 16.6)3.2 (2.2 to 4.6)
Limitation of arm movement: Mild (n = 888, 863)12.4 (10.3 to 14.7)2.5 (1.6 to 3.8)
Limitation of arm movement: Moderate (n =883, 860)1.7 (1.0 to 2.8)0.5 (0.1 to 1.2)
Limitation of arm movement: Severe (n = 882, 861)1.2 (0.6 to 2.2)0.7 (0.3 to 1.5)
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination

Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain \[new muscle/joint pain\], aggravated generalized muscle/joint pain \[aggravated muscle/joint pain\], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(\<38 degrees C); Mild(greater than or equal to \[\>=\]38 to \<38.5 degrees C); Moderate(\>=38.5 to \<39 degrees C); Severe(\>=39 to less than or equal to \[\<=\]40 degrees C); Potentially life threatening (\>40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours \[hrs\]); Moderate(\>2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(\>=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.

Time frame:
Within 7 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination
percentage of participants13vPnCPlacebo
Fever: >=38 to <38.5 degrees C (n = 883, 859)1.1 (0.5 to 2.1)0.6 (0.2 to 1.4)
Fever: >=38.5 to <39 degrees C (n = 881, 859)0.6 (0.2 to 1.3)0.2 (0.0 to 0.8)
Fever: >=39 to =<40 degrees C (n = 882, 859)0.7 (0.3 to 1.5)0.2 (0.0 to 0.8)
Fever: >40 degrees C (n = 882, 860)0.8 (0.3 to 1.6)0.3 (0.1 to 1.0)
Fatigue: Mild (n = 892, 871)13.8 (11.6 to 16.2)11.7 (9.7 to 14.0)
Fatigue: Moderate (n = 886, 866)7.8 (6.1 to 9.8)6.2 (4.7 to 8.1)
Fatigue: Severe (n = 883, 863)1.4 (0.7 to 2.4)0.9 (0.4 to 1.8)
Headache: Mild (n = 891, 870)13.0 (10.9 to 15.4)13.1 (10.9 to 15.5)
Headache: Moderate (n = 883, 868)5.2 (3.8 to 6.9)3.8 (2.6 to 5.3)
Headache: Severe (n = 881, 861)0.6 (0.2 to 1.3)0.6 (0.2 to 1.3)
Chills (n = 891, 866)9.4 (7.6 to 11.5)8.4 (6.7 to 10.5)
Rash (n = 882, 860)3.3 (2.2 to 4.7)0.8 (0.3 to 1.7)
Vomiting: Mild (n = 881, 860)0.0 (0.0 to 0.4)0.7 (0.3 to 1.5)
Vomiting: Moderate (n =881, 860)0.1 (0.0 to 0.6)0.1 (0.0 to 0.6)
Vomiting: Severe (n = 881, 860)0.2 (0.0 to 0.8)0.1 (0.0 to 0.6)
Decreased appetite (n = 886, 865)5.3 (3.9 to 7.0)3.7 (2.5 to 5.2)
Diarrhea: Mild (n = 887, 868)5.1 (3.7 to 6.7)7.7 (6.0 to 9.7)
Diarrhea: Moderate (n = 882, 863)1.2 (0.6 to 2.2)1.0 (0.5 to 2.0)
Diarrhea: Severe (n = 881, 862)0.7 (0.3 to 1.5)0.5 (0.1 to 1.2)
New muscle pain: Mild (n = 894, 865)14.5 (12.3 to 17.0)6.7 (5.1 to 8.6)
New muscle pain: Moderate (n = 886, 863)5.9 (4.4 to 7.6)2.8 (1.8 to 4.1)
New muscle pain: Severe (n = 882, 860)0.7 (0.3 to 1.5)0.5 (0.1 to 1.2)
Aggravated muscle pain: Mild (n = 886, 862)4.6 (3.3 to 6.2)1.9 (1.1 to 3.0)
Aggravated muscle pain: Moderate (n = 885, 863)5.1 (3.7 to 6.7)2.8 (1.8 to 4.1)
Aggravated muscle pain: Severe (n = 882, 860)0.7 (0.3 to 1.5)0.1 (0.0 to 0.6)
New joint pain: Mild (n = 884, 862)5.0 (3.6 to 6.6)3.9 (2.7 to 5.5)
New joint pain: Moderate (n = 883, 864)2.9 (1.9 to 4.3)2.2 (1.3 to 3.4)
New joint pain: Severe (n = 882, 860)0.3 (0.1 to 1.0)0.3 (0.1 to 1.0)
Aggravated joint pain: Mild (n = 883, 861)2.3 (1.4 to 3.5)1.7 (1.0 to 2.9)
Aggravated joint pain: Moderate (n = 884, 862)3.2 (2.1 to 4.5)2.6 (1.6 to 3.8)
Aggravated joint pain: Severe (n = 882, 860)0.3 (0.1 to 1.0)0.3 (0.1 to 1.0)
Use of medication to treat pain (n = 887, 872)8.0 (6.3 to 10.0)6.2 (4.7 to 8.0)
Use of medication to treat fever (n = 883, 863)3.2 (2.1 to 4.6)1.5 (0.8 to 2.6)
Other pre-specifiedPercentage of Participants Who Died

Deaths collected throughout the case acquisition period were presented.

Time frame:
From signing of informed consent form up to case acquisition period defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participants13vPnCPlacebo
Percentage of Participants Who Died7.17.1
Statistical analysis
  • 13vPnC vs Placebo · Fisher Exact · p = 0.979
Other pre-specifiedPercentage of Participants With Newly Diagnosed Chronic Medical Condition

Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.

Time frame:
From 1 month after vaccination up to 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Condition
percentage of participants13vPnCPlacebo
Percentage of Participants With Newly Diagnosed Chronic Medical Condition1.71.2
Statistical analysis
  • 13vPnC vs Placebo · Fisher Exact · p = 0.455

Adverse events

Collected over Safety set (SAEs: Day 1 up to 1 month after vaccination); Immunogenicity subset (SAEs:1 month up to 6 month after vaccination; Other AEs: Day 1 up to 1 month after vaccination; pre-specified local reactions, systemic events:up to 7 days after vaccination). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Safety Set—327/42,237 (0.8%)—
Placebo Safety Set—314/42,255 (0.7%)—
13vPnC Immunogenicity Subset—55/1,006 (5.5%)363/1,006 (36.1%)
Placebo Immunogenicity Subset—48/1,005 (4.8%)315/1,005 (31.3%)
Most frequent serious events
Showing 10 of 281
Most frequent serious events
Event13vPnC Safety SetPlacebo Safety Set13vPnC Immunogenicity SubsetPlacebo Immunogenicity Subset
OsteoarthritisMusculoskeletal and connective tissue disorders1/422370/422552/100610/1005
Cardiac failureCardiac disorders7/4223710/422554/10060/1005
PneumoniaInfections and infestations14/422376/422554/10061/1005
Angina pectorisCardiac disorders19/4223719/422553/10061/1005
Atrial fibrillationCardiac disorders13/422379/422553/10061/1005
Cerebrovascular accidentNervous system disorders9/422378/422553/10061/1005
Ankle fractureInjury, poisoning and procedural complications2/422371/422550/10062/1005
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/422377/422550/10062/1005
Wound infectionInfections and infestations0/422372/422552/10061/1005
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/422370/422552/10061/1005
Most frequent other events
Showing 10 of 176
Most frequent other events
Event13vPnC Safety SetPlacebo Safety Set13vPnC Immunogenicity SubsetPlacebo Immunogenicity Subset
Pain: AnySkin and subcutaneous tissue disorders——330/91453/863
Pain: MildSkin and subcutaneous tissue disorders——300/91348/861
New generalized muscle pain: MildGeneral disorders——130/89458/865
Limitation of arm movement: AnySkin and subcutaneous tissue disorders——126/89128/865
Fatigue: MildGeneral disorders——123/892102/871
Headache: MildGeneral disorders——116/891114/870
Limitation of arm movement: MildSkin and subcutaneous tissue disorders——110/88822/863
ChillsGeneral disorders——84/89173/866
Fatigue: ModerateGeneral disorders——69/88654/866
Diarrhea: MildGeneral disorders——45/88767/868

Baseline characteristics

Safety population included all participants who received study vaccine and who had any safety data.

Age, Continuous
Age, Continuous(years)13vPnCPlaceboTotal
Mean72.8 ± 5.772.8 ± 5.672.8 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)13vPnCPlaceboTotal
Female187901845437244
Male234472380147248
08

Study locations

159 sites
  • Pfizer Investigational Site
    Tilburg, Noord Brabant 5022 JB, Netherlands
  • Pfizer Investigational Site
    Abbekerk, 1657 AH, Netherlands
  • Pfizer Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • Pfizer Investigational Site
    Alkmaar, 1825 PV, Netherlands
  • Pfizer Investigational Site
    Almelo, 7609 PP, Netherlands
  • Pfizer Investigational Site
    Almere, 1315 RA, Netherlands
  • Pfizer Investigational Site
    Almere, 1355 EA, Netherlands
  • Pfizer Investigational Site
    Alphen aan de Rijn, 2402 EP, Netherlands
  • Pfizer Investigational Site
    Amersfoort, 3813 TZ, Netherlands
  • Pfizer Investigational Site
    Amersfoort, 3821 AR, Netherlands
  • Pfizer Investigational Site
    Amstelveen, 1186 AM, Netherlands
  • Pfizer Investigational Site
    Amstelveen, 1186 DA, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1043 GR, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1061 AE, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1066 EC, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1091 AC, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1098 NJ, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • Pfizer Investigational Site
    Apeldoorn, 7333 NS, Netherlands
  • Pfizer Investigational Site
    Apeldoorn, 7334 DZ, Netherlands
  • Pfizer Investigational Site
    Apeldoorn, 7336 BA, Netherlands
  • Pfizer Investigational Site
    Arnhem, 6815 AD, Netherlands
  • Pfizer Investigational Site
    Arnhem, 6842 CT, Netherlands
  • Pfizer Investigational Site
    Assen, 9401 RK, Netherlands
  • Pfizer Investigational Site
    Assen, 9406 GT, Netherlands
  • Pfizer Investigational Site
    Baarle-Nassau, 5111 BX, Netherlands
  • Pfizer Investigational Site
    Baarn, 3743 CM, Netherlands
  • Pfizer Investigational Site
    Bedum, 9781 JG, Netherlands
  • Pfizer Investigational Site
    Bennebroek, 2121 AJ, Netherlands
  • Pfizer Investigational Site
    Bergen op Zoom, 4611 RD, Netherlands
  • Pfizer Investigational Site
    Bergen op Zoom, 4624 VT, Netherlands
  • Pfizer Investigational Site
    Berkel Enschot, 5056 PP, Netherlands
  • Pfizer Investigational Site
    Berkhout, 1647 ME, Netherlands
  • Pfizer Investigational Site
    Bilthoven, 3723 BM, Netherlands
  • Pfizer Investigational Site
    Blaricum, 1261 AN, Netherlands
  • Pfizer Investigational Site
    Breda, 4811 VC, Netherlands
  • Pfizer Investigational Site
    Breda, 4818 CK, Netherlands
  • Pfizer Investigational Site
    Breda, 4835 ND, Netherlands
  • Pfizer Investigational Site
    Brunssum, 6444 AT, Netherlands
  • Pfizer Investigational Site
    Deventer, 7416 SE, Netherlands
  • Pfizer Investigational Site
    Deventer, 7418 EV, Netherlands
  • Pfizer Investigational Site
    Dongen, 5104 JK, Netherlands
  • Pfizer Investigational Site
    Eelde, 9761 AB, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5600 HK, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5611 ZB, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5616 BA, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5631 BM, Netherlands
  • Pfizer Investigational Site
    Emmen, 7811 HN, Netherlands
  • Pfizer Investigational Site
    Emmen, 7824 AA, Netherlands
  • Pfizer Investigational Site
    Enschede, 7513 ER, Netherlands
  • Pfizer Investigational Site
    Enschede, 7521 AG, Netherlands
  • Pfizer Investigational Site
    Epe, 8162 BD, Netherlands
  • Pfizer Investigational Site
    Ettenleur, 4876 AS, Netherlands
  • Pfizer Investigational Site
    Fijnaart, 4793 CB, Netherlands
  • Pfizer Investigational Site
    Geldrop, 5664 EH, Netherlands
  • Pfizer Investigational Site
    Geldrop, 5664 EP, Netherlands
  • Pfizer Investigational Site
    Geldrop, 5664 HV, Netherlands
  • Pfizer Investigational Site
    Goirle, 5051 RJ, Netherlands
  • Pfizer Investigational Site
    Gouda, 2803 AH, Netherlands
  • Pfizer Investigational Site
    Gouda, 2803 PL, Netherlands
  • Pfizer Investigational Site
    Groningen, 9713 EC, Netherlands
  • Pfizer Investigational Site
    Groningen, 9713 GZ, Netherlands
  • Pfizer Investigational Site
    Groningen, 9728 NT, Netherlands
  • Pfizer Investigational Site
    Groningen, 9733 CA, Netherlands
  • Pfizer Investigational Site
    Grootebroek, 1613 SJ, Netherlands
  • Pfizer Investigational Site
    Haarlem, 2035 RC, Netherlands
  • Pfizer Investigational Site
    Haarlem, 2035 RJ, Netherlands
  • Pfizer Investigational Site
    Haren, 9751 ND, Netherlands
  • Pfizer Investigational Site
    Harmelen, 3481 EN, Netherlands
  • Pfizer Investigational Site
    Heerhugowaard, 1701 GB, Netherlands
  • Pfizer Investigational Site
    Heerlen, 6412 CD, Netherlands
  • Pfizer Investigational Site
    Heerlen, 6419 PC, Netherlands
  • Pfizer Investigational Site
    Heiloo, Netherlands
  • Pfizer Investigational Site
    Helmond, 5707 HA, Netherlands
  • Pfizer Investigational Site
    Hengelo, 7555 BB, Netherlands
  • Pfizer Investigational Site
    Hengelo, 7555 DL, Netherlands
  • Pfizer Investigational Site
    Hilvarenbeek, 5081JV, Netherlands
  • Pfizer Investigational Site
    Hilversum, 1213 XZ, Netherlands
  • Pfizer Investigational Site
    Hilversum, 1217 GP, Netherlands
  • Pfizer Investigational Site
    Hoofddorp, 2134 TM, Netherlands
  • Pfizer Investigational Site
    Hoogezand, 9601 KE�, Netherlands
  • Pfizer Investigational Site
    Hoorn, 1624 NP, Netherlands
  • Pfizer Investigational Site
    Hoorn, 1628 LZ, Netherlands
  • Pfizer Investigational Site
    Hoorn, 1642 NP, Netherlands
  • Pfizer Investigational Site
    Houten, 3995 AA, Netherlands
  • Pfizer Investigational Site
    Kampen, 8266 AB, Netherlands
  • Pfizer Investigational Site
    Katwijk, 2223 BM, Netherlands
  • Pfizer Investigational Site
    Kerkrade, 6461 AL, Netherlands
  • Pfizer Investigational Site
    Leek, 9351 KP, Netherlands
  • Pfizer Investigational Site
    Leeuwarden, 8915 AC, Netherlands
  • Pfizer Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • Pfizer Investigational Site
    Leiden, 2316 XC, Netherlands
  • Pfizer Investigational Site
    Leiden, 2333 ZA, Netherlands
  • Pfizer Investigational Site
    Leiden, 2334 CK, Netherlands
  • Pfizer Investigational Site
    Leiderdorp, 2353 GA, Netherlands
  • Pfizer Investigational Site
    Maarssen, 3603 BM, Netherlands
  • Pfizer Investigational Site
    Maastricht, 6227 BZ, Netherlands
  • Pfizer Investigational Site
    Maastricht, 6229 HX, Netherlands

Showing the first 100 of 159 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018 Mar 7;36(11):1477-1483. doi: 10.1016/j.vaccine.2018.01.049. Epub 2018 Feb 9. PubMed 29429807 ↗
  • van Deursen AMM, van Houten MA, Webber C, Patton M, Scott DA, Patterson S, Sidhu M, Drews W, Gruber WC, Emini EA, Grobbee DE, Bonten MJM, Sanders EAM. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017 Sep 1;65(5):787-795. doi: 10.1093/cid/cix419. PubMed 29017280 ↗
  • Huijts SM, van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017 Aug 3;35(34):4444-4449. doi: 10.1016/j.vaccine.2017.01.071. Epub 2017 Apr 12. PubMed 28410813 ↗
  • Webber C, Patton M, Patterson S, Schmoele-Thoma B, Huijts SM, Bonten MJ; CAPiTA Study Group. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017 Mar 1;35(9):1266-1272. doi: 10.1016/j.vaccine.2017.01.032. Epub 2017 Feb 4. PubMed 28173960 ↗
  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544. PubMed 25785969 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2008
First posted
Aug 29, 2008
Start
Sep 2008
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 6, 2014
Last update
Oct 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00744263
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 29, 2008
Start date
Sep 2008
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 6, 2014
Last update
Oct 6, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion